Mostrando 2 resultados de: 2
Filtros aplicados
Subtipo de publicación
Article(2)
Publisher
Frontiers in Pharmacology(2)
Área temáticas
Enfermedades(2)
Objetivos de Desarrollo Sostenible
ODS 10: Reducción de las desigualdades(2)
ODS 17: Alianzas para lograr los objetivos(2)
ODS 3: Salud y bienestar(2)
Origen
scopus(2)
Nimotuzumab induces NK cell activation, cytotoxicity, dendritic cell maturation and expansion of EGFR-specific T cells in head and neck cancer patients
ArticleAbstract: Survival benefit and long-term duration of clinical response have been seen using the epidermal growPalabras claves:head and neck cancer, Human epidermal growth factor receptor, monoclonal antibodies, Natural killer cells, T cellsAutores:Barroso M.C., Concha-Benavente F., Crombet-Ramos T., Cuevas I., Ferris R.L., Frómeta C., García-Bates T.M., González A., Gonzalez Z., Hechavarría E., Lavastida A., Lugiollo M., Mazorra Z., Mestre B.F., Srivastava R.M., Valdés A.Fuentes:scopusSafety and immunogenicity of a human epidermal growth factor receptor 1 (HER1)-based vaccine in prostate castration-resistant carcinoma patients: A dose-escalation phase I study trial
ArticleAbstract: Metastatic castration-resistant prostate cancer (CRPC) remains incurable due to the lack of effectivPalabras claves:Human epidermal growth factor receptor, Immunogenicity, Prostate cancer, safety, Therapeutic vaccineAutores:Aira L.E., Bárbara Wilkinson, Caballero I., Casacó Parada A.R., Coba K., Crombet-Ramos T., González J.G., González N., Joaquín González, Lavastida A., Luaces P.L.o., Macías A.E., Mazorra Z., Mesa M., Popa X., Rivero J., Sanchez B., Santiesteban Y., Suárez E., Troche M.Fuentes:scopus